Jiangsu Nhwa Pharmaceutical (002262) H1 2025 earnings summary

Executive summary

• Achieved revenue of ¥3.01 billion, up 8.93% year-over-year, and net profit attributable to shareholders of ¥700.49 million, up 11.38% year-over-year.

• Focused on R&D, production, and sales of CNS drugs, maintaining leading positions in anesthesia, psychiatric, and neurological drug markets.

• Increased R&D investment by 23.97% to ¥395.33 million, with 70+ projects in the pipeline and 17 innovative drugs under development.

• Expanded digital healthcare and precision medicine, with significant progress in online mental health services and AI-driven diagnostics.

Financial highlights

• Operating income: ¥3,010,121,701.84, up 8.93% year-over-year.

• Net profit attributable to shareholders: ¥700,494,742.07, up 11.38% year-over-year.

• Basic and diluted EPS: ¥0.69, up 11.29% year-over-year.

• Operating cash flow: ¥494,823,199.32, down 20.43% year-over-year.

• Gross margin for anesthesia, psychiatric, and neurological drugs remained high, with anesthesia at 90.80%.

Outlook and guidance

• Will continue to focus on CNS drug innovation, expand digital and precision medicine, and strengthen market leadership.

• Plans to accelerate new product launches and enhance R&D for both innovative and generic drugs.

• No interim dividend, bonus shares, or capital increase from reserves planned for the half-year.